Screening for depression in children and adolescents: a protocol for a systematic review update.
Depression
adolescent
child
children
screening
systematic review
youth
Journal
Systematic reviews
ISSN: 2046-4053
Titre abrégé: Syst Rev
Pays: England
ID NLM: 101580575
Informations de publication
Date de publication:
12 01 2021
12 01 2021
Historique:
received:
05
05
2020
accepted:
21
12
2020
entrez:
13
1
2021
pubmed:
14
1
2021
medline:
25
6
2021
Statut:
epublish
Résumé
Major depressive disorder is common, debilitating, and affects feelings, thoughts, mood, and behaviors. Childhood and adolescence are critical periods for the development of depression and adolescence is marked by an increased incidence of mental health disorders. This protocol outlines the planned scope and methods for a systematic review update that will evaluate the benefits and harms of screening for depression in children and adolescents. This review will update a previously published systematic review by Roseman and colleagues. Eligible studies are randomized controlled trials (RCTs) assessing formal screening in primary care to identify children or adolescents not already self-reporting symptoms of, diagnosed with, or treated for depression. If no or only a single RCT is available, we will consider controlled studies without random assignment. Studies of participants with characteristics associated with an elevated risk of depression will be analyzed separately. Outcomes of interest are symptoms of depression, classification of major depressive disorder based on a validated diagnostic interview, suicidality, health-related quality of life, social function, impact on lifestyle behavior (e.g., substance use, school performance, lost time at work, or school), false-positive results, overdiagnosis, overtreatment, labeling, and other harms such as those arising from treatment. We will search MEDLINE, Embase, PsycINFO, CINAHL, the Cochrane Library, and grey literature sources. Two reviewers will independently screen the titles and abstracts using the liberal accelerated method. Full-text screening will be performed independently by two reviewers using pre-specified eligibility criteria. Data extraction and risk of bias assessments will be performed independently by two reviewers. Pre-planned analyses, including subgroup and sensitivity analyses, are detailed within this protocol. Two independent reviewers will assess and finalize through consensus the certainty of evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, and prepare GRADE evidence profiles and summary of findings tables for each outcome of interest. The systematic review will provide a current state of the evidence of benefits and harms of depression screening in children and adolescents. These findings will be used by the Canadian Task Force on Preventive Health Care to inform the development of recommendations on depression screening. PROSPERO CRD42020150373.
Sections du résumé
BACKGROUND
Major depressive disorder is common, debilitating, and affects feelings, thoughts, mood, and behaviors. Childhood and adolescence are critical periods for the development of depression and adolescence is marked by an increased incidence of mental health disorders. This protocol outlines the planned scope and methods for a systematic review update that will evaluate the benefits and harms of screening for depression in children and adolescents.
METHODS
This review will update a previously published systematic review by Roseman and colleagues. Eligible studies are randomized controlled trials (RCTs) assessing formal screening in primary care to identify children or adolescents not already self-reporting symptoms of, diagnosed with, or treated for depression. If no or only a single RCT is available, we will consider controlled studies without random assignment. Studies of participants with characteristics associated with an elevated risk of depression will be analyzed separately. Outcomes of interest are symptoms of depression, classification of major depressive disorder based on a validated diagnostic interview, suicidality, health-related quality of life, social function, impact on lifestyle behavior (e.g., substance use, school performance, lost time at work, or school), false-positive results, overdiagnosis, overtreatment, labeling, and other harms such as those arising from treatment. We will search MEDLINE, Embase, PsycINFO, CINAHL, the Cochrane Library, and grey literature sources. Two reviewers will independently screen the titles and abstracts using the liberal accelerated method. Full-text screening will be performed independently by two reviewers using pre-specified eligibility criteria. Data extraction and risk of bias assessments will be performed independently by two reviewers. Pre-planned analyses, including subgroup and sensitivity analyses, are detailed within this protocol. Two independent reviewers will assess and finalize through consensus the certainty of evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, and prepare GRADE evidence profiles and summary of findings tables for each outcome of interest.
DISCUSSION
The systematic review will provide a current state of the evidence of benefits and harms of depression screening in children and adolescents. These findings will be used by the Canadian Task Force on Preventive Health Care to inform the development of recommendations on depression screening.
SYSTEMATIC REVIEW REGISTRATION
PROSPERO CRD42020150373.
Identifiants
pubmed: 33436094
doi: 10.1186/s13643-020-01568-3
pii: 10.1186/s13643-020-01568-3
pmc: PMC7802305
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
24Références
Ann Intern Med. 2016 Mar 1;164(5):342-9
pubmed: 26857836
BMJ. 2015 Jan 02;350:g7647
pubmed: 25555855
Lancet. 2012 Mar 17;379(9820):1056-67
pubmed: 22305766
J Abnorm Psychol. 1998 Feb;107(1):128-40
pubmed: 9505045
J Clin Epidemiol. 2020 Mar;119:126-135
pubmed: 31711912
Neuroscience. 2013 Sep 26;249:162-71
pubmed: 23123920
Aust N Z J Psychiatry. 2015 Oct;49(10):869-86
pubmed: 26416916
Br J Psychiatry. 2004 May;184:393-403
pubmed: 15123502
JAMA. 1999 May 12;281(18):1707-13
pubmed: 10328070
Soc Psychiatry Psychiatr Epidemiol. 2016 Feb;51(2):203-10
pubmed: 26743882
J Clin Epidemiol. 2011 Apr;64(4):401-6
pubmed: 21208779
Clin Psychol Rev. 2014 Dec;34(8):595-607
pubmed: 25455624
J Am Acad Child Adolesc Psychiatry. 2002 Feb;41(2):190-8
pubmed: 11837409
Pediatrics. 2007 Nov;120(5):e1299-312
pubmed: 17974723
Can J Psychiatry. 2006 Feb;51(2):84-90
pubmed: 16989107
Ann Intern Med. 2016 Mar 1;164(5):360-6
pubmed: 26858097
J Child Psychol Psychiatry. 2011 Oct;52(10):1015-25
pubmed: 21815892
PLoS Med. 2009 Jul 21;6(7):e1000100
pubmed: 19621070
Syst Rev. 2012 Feb 10;1:10
pubmed: 22587960
Syst Rev. 2019 Jan 19;8(1):27
pubmed: 30660183
J Adolesc. 2014 Jun;37(4):335-46
pubmed: 24793380
Nat Rev Dis Primers. 2016 Sep 15;2:16065
pubmed: 27629598
J Affect Disord. 2018 Feb;227:56-64
pubmed: 29053976
Clin Psychol Sci. 2013 Jan;1(1):
pubmed: 24273703
J Am Acad Child Adolesc Psychiatry. 2019 Jan;58(1):72-79
pubmed: 30577941
Br J Psychiatry. 2010 Dec;197(6):433-40
pubmed: 21119148
CMAJ. 2005 Jan 4;172(1):33-5
pubmed: 15632399
BMC Med. 2017 Aug 9;15(1):150
pubmed: 28789659
J Affect Disord. 2018 Dec 1;241:256-262
pubmed: 30138810
J Clin Epidemiol. 2016 Jul;75:40-6
pubmed: 27005575
Psychol Bull. 2006 Jan;132(1):132-49
pubmed: 16435960
J Clin Epidemiol. 2011 Nov;64(11):1187-97
pubmed: 21477993
Med Care. 1984 Dec;22(12):1101-14
pubmed: 6513619
BMJ. 2017 Sep 21;358:j4008
pubmed: 28935701
Cochrane Database Syst Rev. 2012 Nov 14;11:CD004851
pubmed: 23152227
J Clin Epidemiol. 2013 Feb;66(2):173-83
pubmed: 23116689
Lancet. 2016 Aug 27;388(10047):881-90
pubmed: 27289172
Pediatrics. 2012 May;129(5):925-49
pubmed: 22473374
Prev Med. 2015 Apr;73:133-8
pubmed: 25657166
Am J Psychiatry. 2007 Oct;164(10):1539-46
pubmed: 17898345
J Affect Disord. 2017 Mar 01;210:22-26
pubmed: 28012349
Health Technol Assess. 2003;7(41):1-90
pubmed: 14670218
BMC Med. 2014 Jan 28;12:13
pubmed: 24472580
Eur Child Adolesc Psychiatry. 2015 Jun;24(6):641-50
pubmed: 24723042
J Affect Disord. 2014 Mar;156:8-23
pubmed: 24308895
J Affect Disord. 2014 Dec;169:61-75
pubmed: 25154536
Ir J Psychol Med. 2015 Mar;32(1):93-105
pubmed: 30185277
J Psychosom Res. 2014 Jun;76(6):433-46
pubmed: 24840137
Depress Anxiety. 2018 Aug;35(8):700-716
pubmed: 29878410
BMJ. 2004 Jun 19;328(7454):1490
pubmed: 15205295
Can J Psychiatry. 2019 Apr;64(4):246-255
pubmed: 30978138
Syst Rev. 2014 Jun 23;3:60
pubmed: 24956937
J Psychosom Res. 2018 Jun;109:9-11
pubmed: 29773154
Can J Psychiatry. 2017 Dec;62(12):813-817
pubmed: 28851234
Clin Trials. 2005;2(2):141-51
pubmed: 16279136
CMAJ. 2013 Jun 11;185(9):753-4
pubmed: 23670151
Syst Rev. 2015 Nov 18;4:166
pubmed: 26581392
BMC Med Res Methodol. 2012 Jun 12;12:76
pubmed: 22691262
Pediatrics. 2018 Mar;141(3):
pubmed: 29483200
Lancet. 2011 Jun 18;377(9783):2093-102
pubmed: 21652063
BMJ. 2001 Jul 14;323(7304):101-5
pubmed: 11451790
Lancet. 2007 Mar 31;369(9567):1130-9
pubmed: 17398312
Prev Med. 2016 Jul;88:147-52
pubmed: 27090920
BMJ. 2011 Jul 22;343:d4002
pubmed: 21784880
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120